GBS - GBS Inc.: Can Its Technology Come Through?

• GBS is a biotechnology company aiming to utilize saliva as a medium for developing non-invasive diagnostic tests. The companies pipeline products are targeting both the COVID-19 and Diabetes markets.
• GBS currently trades at around $3, which is an attractive entry point for investors.
• However - The high technological risk associated with its technology outweighs the low entry point.
• Technological Risk mainly stems from the fact that scientific literature disagrees over the reliability and accuracy of using saliva as a diagnostic medium.

For further details see: